ArticleFrontiers in cardiovascular medicine2025
Single center experience with surgically implanted Melody and Sapien 3 valves in the mitral position in young children.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Evolving Frontier of Repeat Transcatheter Valve-in-Valve Mitral Interventions in Small Children.JACC. Case reports · 2026Article
- Modified Melody Valve Surgical Implantation in Atrioventricular Position in Four Children Under Two Years of Age.Pediatric cardiology · 2026Article
- Management and Imaging Strategies in Pediatric Infective Endocarditis With Mitral Prolapse.JACC. Case reports · 2026Article
- Reply: Management and Imaging Strategies in Pediatric Infective Endocarditis With Mitral Prolapse.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Mitral valve replacement in young children is a challenging situation due to limited options. In this study, we aimed to present the results of our patients who underwent mitral valve replacement using Melody (Medtronic Inc) and Sapien 3 (Edwards Inc) valves. Methods: We performed a total of 18 mitral valve replacements at Phoenix Children's between 2017 and 2024. These include 12 Melody and 6 Sapien valves. The median patient age was 42.17 ± 38.9 (1.9-127.2) months and weight was 13.83 ± 9.38 (3.9-43.4) kg, respectively. The indications for implantation were mitral stenosis with or without regurgitation, following an atrioventricular septal defect (AVSD) repair, mitral valve dysplasia, and Shone's complex. Once positioned the valves were expanded using a balloon catheter to achieve the best diameter (16-30 mm). Results: The postoperative mean mitral gradient was 6 ± 2.91 (2-12) mmHg. A permanent pacemaker was implanted in one patient after Sapien 3 valve replacement. One patient who received a Sapien valve had to be re-intervened for tamponade in the early post operative period. Mild LVOT obstruction was observed in one patient who underwent Melody valve replacement. One Melody valve was dilated after one year after implantation. At 24 months after implantation, Kaplan-Meier analysis indicated that 80% of Melody valves and 83% of Sapien valves would be expected to be free from reoperation (Log-rank Conclusions: Melody and Sapien valves contribute to the prognosis of patients as it shortens the operation time, is easily applicable, and provides opportunities such as postoperative redilation. The successful results we obtained show that both valves can be used reliably and effectively and can be an alternative to conventional methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.